Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Non-Current Debt (2020 - 2025)

Maravai Lifesciences Holdings has reported Non-Current Debt over the past 6 years, most recently at $286.3 million for Q4 2025.

  • Quarterly results put Non-Current Debt at $286.3 million for Q4 2025, down 1.43% from a year ago — trailing twelve months through Dec 2025 was $286.3 million (down 1.43% YoY), and the annual figure for FY2025 was $286.3 million, down 1.43%.
  • Non-Current Debt for Q4 2025 was $286.3 million at Maravai Lifesciences Holdings, roughly flat from $287.4 million in the prior quarter.
  • Over the last five years, Non-Current Debt for MRVI hit a ceiling of $713.5 million in Q4 2021 and a floor of $286.3 million in Q4 2025.
  • Median Non-Current Debt over the past 5 years was $519.1 million (2023), compared with a mean of $492.3 million.
  • Biggest five-year swings in Non-Current Debt: skyrocketed 86.01% in 2022 and later plummeted 44.34% in 2025.
  • Maravai Lifesciences Holdings' Non-Current Debt stood at $713.5 million in 2021, then decreased by 26.84% to $522.0 million in 2022, then dropped by 0.63% to $518.7 million in 2023, then plummeted by 44.0% to $290.5 million in 2024, then fell by 1.43% to $286.3 million in 2025.
  • The last three reported values for Non-Current Debt were $286.3 million (Q4 2025), $287.4 million (Q3 2025), and $288.4 million (Q2 2025) per Business Quant data.